Institute for Evidence in Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany.
BMJ Open. 2022 May 9;12(5):e060255. doi: 10.1136/bmjopen-2021-060255.
We investigated characteristics of systematic reviews (SRs) assessing measures to prevent COVID-19 by (1) identifying SR registrations in Prospective Register of Systematic Reviews (PROSPERO), (2) identifying published SRs in COVID-19 Living Overview of the Evidence (L-OVE) and (3) estimating the proportion of PROSPERO registrations published as full SR between 8 and 16 months after registration.
This meta-research study is part of the German CEOsys project, www.covid-evidenz.de. We searched PROSPERO entries registered between 1 January 2020 and 31 August 2020, and we searched COVID-19 L-OVE for published SRs (search date: 5 May 2021) focusing on measures to prevent COVID-19 and SARS-CoV-2 transmission. The two samples were screened for eligibility and key characteristics were extracted and summarised.
Of 612 PROSPERO registrations, 47 focused on prevention and were included. The preventive measures included public health interventions (20), followed by personal protective equipment (10), vaccinations (9) and others (8). In total, 13 of 47 (28%) PROSPERO registrations had been published as full SR (as preprint only (6), as peer-reviewed article only (6), as preprint and peer-reviewed article (1)). Median time between PROSPERO registration and publication was 5 months for peer-reviewed SRs and 2 months for preprints.Of the 2182 entries identified in COVID-19 L-OVE, 51 published SRs focused on prevention and were included. Similar to the PROSPERO sample, most published SRs focused on public health interventions (21). The number of included primary studies ranged between 0 and 64 (median: 7). Nine published SRs did not include any studies because of a lack of primary studies.
Considering the urgent information needs of policymakers and the public, our findings reveal the high-speed publication of preprints and lack of primary studies in the beginning of the COVID-19 crisis. Further meta-research on COVID-19 SRs is important to improve research efficiency among researchers across the world.
CRD42021240423.
通过(1)在系统评价注册资料库(PROSPERO)中确定针对 COVID-19 的预防措施的系统评价(SR)注册,(2)在 COVID-19 证据综述(L-OVE)中确定已发表的 SR,以及(3)估计在注册后 8 至 16 个月内将 PROSPERO 注册作为完整 SR 发表的比例,来调查评估预防 COVID-19 的措施的 SR 特征。
这是德国 CEOsys 项目的一部分,网址为 www.covid-evidenz.de。我们在 2020 年 1 月 1 日至 2020 年 8 月 31 日之间搜索了 PROSPERO 条目,并在 COVID-19 L-OVE 中搜索了已发表的 SR(搜索日期:2021 年 5 月 5 日),重点关注预防 COVID-19 和 SARS-CoV-2 传播的措施。这两个样本都经过了资格筛选,提取并总结了关键特征。
在 612 个 PROSPERO 注册中,有 47 个关注预防措施并被纳入。预防措施包括公共卫生干预措施(20 个),其次是个人防护设备(10 个)、疫苗接种(9 个)和其他措施(8 个)。在 47 个 PROSPERO 注册中,有 13 个(28%)已作为完整的 SR 发表(仅为预印本(6 个)、仅为同行评审文章(6 个)、预印本和同行评审文章(1 个))。在 PROSPERO 注册和发表之间的中位数时间为同行评审的 SR 为 5 个月,预印本为 2 个月。在 COVID-19 L-OVE 中确定的 2182 个条目,有 51 篇发表的 SR 关注预防措施并被纳入。与 PROSPERO 样本类似,大多数已发表的 SR 重点关注公共卫生干预措施(21 篇)。纳入的初级研究数量在 0 至 64 之间(中位数:7)。由于缺乏初级研究,有 9 篇发表的 SR 未包括任何研究。
考虑到决策者和公众的紧急信息需求,我们的研究结果揭示了在 COVID-19 危机开始时,预印本的快速发表和初级研究的缺乏。对 COVID-19 SR 的进一步元研究对于提高全球研究人员的研究效率非常重要。
PROSPERO 注册编号:CRD42021240423。